Physician profile
Glenn Campbell
NPI 1740337500
$2,364.94
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $515 · 2021: $75.21 · 2022: $872 · 2023: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $403.12 | 2021-2023 | Hydrus Microstent |
| Abbvie INC. | $390.71 | 2022-2023 | Durysta |
| Allergan, INC. | $381.50 | 2019-2021 | |
| Sight Sciences, INC. | $307.06 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $235.69 | 2022-2023 | Miebo, Vyzulta |
| Mallinckrodt Hospital Products INC. | $191.31 | 2020-2023 | Acthar |
| Ocular Therapeutix, INC. | $110.16 | 2020-2023 | Dextenza |
| Ivantis, INC | $68.66 | 2020 | |
| Mallinckrodt Enterprises LLC | $46.24 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.01 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $38.24 | 2022 | |
| Topcon Healthcare, INC. | $32.96 | 2019 | |
| Rayner Intraocular Lenses Limited | $31.86 | 2022-2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Kala Pharmaceuticals, INC. | $24.64 | 2019 | |
| Sun Pharmaceutical Industries INC. | $23.56 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $19.50 | 2020 | |
| Biotissue Holdings INC. | $18.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.